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The complement protein C3d and C3d derived peptides that bind CD21 are known to enhance immunity to co-immunised antigens. In this study we have synthesised the minimal CD21 binding sequence of C3d (1227LYNVEA1232) as mono, di and tri tandem repeats and derivatised the N-terminus with an acryloyl moiety. These acryloyl-(C3d)n peptides were co-polymerised with a acryloyl-T cell epitope (PAS1K) from the Porphyromonas gingivalis antigen the RgpA-Kgp proteinase-adhesin complex. The ability of C3d containing polymers to enhance T cell immunity in-vitro and in-vivo was evaluated. When used to stimulate in-vitro PAS1K-primed or RgpA-Kgp complex-primed T cells the C3d containing PAS1K polymers induced a mixed and significantly (p<0.05) higher IL-4 and IFNγ T cell response compared to that induced by the PAS1K peptide or polymer. PAS1K polymers containing tandem repeats of C3d induced a significantly (p<0.05) stronger maximal proliferative response, at the same antigenic dose, compared to that induced by the PAS1K peptide or polymer. When used as immunogens to prime T cells all of the C3d containing PAS1K polymers induced a dominant IFNγ T cell response and reduced the antigen dose required for maximal proliferation 150-fold compared to that required for the PAS1K- peptide or polymer primed T cells. In conclusion, the 6 residue sequence LYNVEA from C3d is sufficient to enhance immunity to an antigen and that the effect is more pronounced when C3d is part of the immunising antigen rather than an in-vitro stimulating antigen.







Complement is typically regarded as a component of the innate immune system, however, degradation products particularly of the third complement factor, C3, are known to enhance the adaptive immune response to foreign antigens (Toapanta and Ross 2006). Activation of C3 leads to the generation of C3dg and its degradation product C3d which form covalent bonds with foreign antigens, thus providing a ligand for complement receptor 2 (CD21). CD21 is expressed on B cells, follicular dendritic cells (FDCs), epithelial cells and subsets of T cells (Hourcade et al. 1989). CD21 engagement with C3d is known to lower the antigen activation threshold in B cells and induce proliferation as well as playing a role in B cell memory and tolerance and immunoglobulin class switching  ADDIN EN.CITE (Fearon 1998; Frade et al. 1992; Mongini et al. 1997; Toapanta and Ross 2006). C3d-antigen complexes have been reported to enhance antigen processing and presentation by FDCs and they are retained on the cell surface for extended periods of time which has been shown to play a role in enhancing B cell activation, antibody production and memory  ADDIN EN.CITE (Bergmann-Leitner et al. 2006; Roozendaal and Carroll 2007; Zabel and Weis 2001). Although, CD21 is expressed on 1-23% of human and 4-5% of mouse T cells the functional role played by CD21 on T cells is yet to be fully elucidated  ADDIN EN.CITE (Levy et al. 1992; Molnar et al. 2008). However, CD21 expressing T cells have been shown to adhere strongly to C3d/CD21 bearing target cells and this enhanced binding is suggested to increase T cell activation and differentiation  ADDIN EN.CITE (Levy et al. 1992; Masilamani et al. 2002; Sinha et al. 1993). In mice, antigen immunisation has been shown to result in the increase in lymph node CD21+ T cells which is enhanced by the presence of C3d/CD21 bearing B cells  ADDIN EN.CITE (Kerekes et al. 1998; Molnar et al. 2008).
	C3d is a 35 kDa protein and although several binding sites for CD21 (CR2) have been postulated a 28 amino acid sequence (1209KFLTTAKDKNRWEDPGKQLYNVEATSYA1236) was found to contain the minimal binding domain 1227LYNVEA1232 (Lambris et al. 1985). Dempsey et al.  ADDIN EN.CITE (1996) have shown that the fusion of C3d to a model antigen, hen egg lysozyme, enhanced the immune response to the antigen and that including 2 or 3 copies of C3d resulted in a 1,000 and 10,000 fold increase in the antibody response, respectively. Inclusion of multiple copies of C3d in either DNA, protein or polysaccharide based vaccines has been shown in several studies to enhance immunogenicity to the vaccine antigen, and a recent study suggests that 6 or more copies of C3d are necessary for efficient enhancement of the immune response  ADDIN EN.CITE (Green et al. 2003; Haas et al. 2004; Lou and Kohler 1998; Mitsuyoshi et al. 2005; Mkrtichyan et al. 2008; Suradhat et al. 2001; Toapanta and Ross 2006; Wang et al. 2006; Zhang et al. 2011). Although, the 28 amino acid C3d binding region peptide is known to have reduced affinity for CD21, its incorporation into a vaccine construct does enhance the immune response to the vaccine antigen and multiple copies of the peptide, up to three have been shown to induce stronger immunity and CD21 affinity than one or two copies of the peptide  ADDIN EN.CITE (Bergmann-Leitner et al. 2007; Bower and Ross 2006; Lou and Kohler 1998; Servis and Lambris 1989; Tsokos et al. 1990). Frade et al.  ADDIN EN.CITE (1992) have shown that a 16 residue synthetic peptide of C3d containing the minimal binding sequence 1227LYNVEA1232 does induce proliferation. In another study the multi-valency of a 13 residue C3d peptide (P13) containing the LYNVEA sequence was found to be essential for activation and proliferation as the multi-valent (four copies of P13) antigen was able to cross link CD21 bearing effector and target cells (Servis and Lambris 1989).






Unless stated otherwise, chemicals used for peptide-resin assembly were of peptide synthesis grade or its equivalent. O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), 1-hydroxybenzotriazole (HOBT), diisopropylethylamine (DIPEA),  dimethylformamide (DMF), trifluoroacetic acid (TFA), piperidine, 9-flourenylmethloxycarbonyl (Fmoc)-protected amino acids, Fmoc-6-amino hexanoic acid (Ahx) and Fmoc-L-Ala-WANG resin were purchased from Auspep Pty. Ltd., Melbourne, Australia while Fmoc-PAL-PEG-PS resin was purchased from PerSeptive Biosystems, Inc., Framingham, MA. Dichloromethane (DCM), diethyl ether, phenol, trishydroxymethylaminomethane (Tris), ethylenediamine tetraacetic acid (EDTA), methanol (MeOH) and ammonium chloride were purchased from Ajax Finechem, New South Wales, Australia. Acrylamide was obtained from BioRad Laboratories, New South Wales, Australia. Acryloyl chloride, acetonitrile, sodium bicarbonate, sodium hydroxide (NaOH) and sodium chloride (NaCl) were obtained from MERCK, Victoria, Australia.  Triisopropylsilane (TIPS), guanidine-HCl, ammonium persulfate, tetramethylethylenediamine (TEMED), Dulbecco's phosphate buffered saline (PBS), complete Freund’s adjuvant (CFA), incomplete Freund’s adjuvant (IFA), Bovine Serum Albumin (BSA), L-glutamine, sodium pyruvate, gentamicin, penicillin, streptomycin, concanavalin A (ConA), N-lauroylsarcosine, and polyoxyethylene sorbitan monolaurate (Tween 20) were purchased from Sigma-Aldrich, New South Wales, Australia. Dulbecco's modified eagle's medium (DMEM) was obtained from SAFC Bioscience, Victoria, Australia.  Fetal bovine serum (FBS) was purchased from GIBCO Invitrogen Corporation, Victoria, Australia. The antibodies (Abs) used in ELISPOT assay were bought from eBiosciences, San Diego, USA. 2-Mercaptoethanol and ammonium bicarbonate were obtained from ICN Biomedicals, Inc., Costa Mesa, USA. 2,4,6-Trinitrobenzene sulfonic acid (TNBSA) was kindly provided in powder form by Dr Denis Scanlon. 

Synthesis and purification of Acryloyl-Peptides
All peptides were synthesised as acryloyl-Ahx-(Lys)4 derivatives and PAS1K (Acryloyl-Ahx-(Lys)4-NYTAHGSETAWADPL, MW: 2311.6 Da) and C3d-based peptides, C3d (Acryloyl-Ahx-(Lys)4-LYNVEA, MW: 1387.7 Da), [C3d]2 (Acryloyl-Ahx-(Lys)4-LYNVEALYNVEA, MW: 2077.5 Da) and [C3d]3 (Acryloyl-Ahx-(Lys)4-LYNVEALYNVEALYNVEA, MW: 2767.2 Da) were synthesized using the LibertyTM Microwave Peptide Synthesizer (CEM Corporation, Matthews, NC, USA). Fmoc chemistry using Fmoc-protected amino acids and Fmoc-PAL-PEG-PS resin (0.20 mmol/g) or Fmoc-L-Ala-WANG (0.70 mmol/g) as the solid support was employed throughout the synthesis, with the completed peptides assembled as their C-terminal carboxyamide (PAS1K) or carboxyl forms (C3d-based peptides). Fmoc-Ahx-OH was manually coupled as a spacer (O'Brien-Simpson et al. 1997) to the N-terminus of each peptide via the addition of HBTU (5 equivalents), HOBT (5 equivalents) and DIPEA (9 equivalents) in DMF. Fmoc-Ahx-OH coupling was monitored by the TNBSA test (Hancock and Battersby 1976) and following a negative TNBSA test, the resin was washed with DMF (1 x 10 ml) and DCM (5 x 10 ml).
Following removal of the Fmoc group [20% piperidine/DMF (v/v; 20 min) the peptide-resin was washed with DMF (6 x 5ml), DCM (6 x 5ml) and diethyl ether (6 x 5ml), then dried under reduced pressure (18h). Acryloylation of the dried Ahx-peptide-resins (0.1 mmol) were carried out manually using 8 fold molar excess of acryloyl chloride (0.8 mmol) and 16 fold molar excess of DIPEA (1.6 mmol) in anhydrous DMF (4 ml) under nitrogen for 1 hour and the reaction monitored using the TNBSA test.
The assembled acryloyl-Ahx-peptides were cleaved from the resin support and side chain deprotected using a mixture containing TFA/H2O/TIPS/phenol (92.5:2.5:2.5:2.5; v/v/v/v; 5 ml) for 2 hours. The TFA/peptide solution was collected by filtration and evaporated to approximately 1 mL under a stream of nitrogen at room temperature and the crude peptides precipitated in ice cold diethyl ether, centrifuged (4,000g), washed with diethyl ether (3 x 40ml) and dried under reduced pressure.
The dried crude peptides were then dissolved in 0.1% (v/v) TFA in milliQ water and purified using a semi-preparative ZORBAX 300 SB-C18 column (9.4 mm x 25 cm) installed in a High Performance Liquid Chromatography (HPLC) 1100 system (Agilent Technologies Pty. Ltd., Victoria, Australia) under a flow rate of 4 ml/min using buffer A (0.1% v/v TFA in milliQ water) and buffer B (0.1% TFA in 90% acetonitrile, 10% milliQ water, v/v) as the limiting solvent. Peptide detection was performed by absorbance at 214 nm. Fractions were collected and identified using electrospray mass spectrometry (Esquire LC-MS, Bruker Daltonics, NSW, Australia).

Polymerization of N-acryloyl-peptides
N-acryloyl-Ahx-(Lys)4-PAS1K was polymerised singularly and with equimole equivalents of either N-acryloyl-Ahx-(Lys)4-C3d, N-acryloyl-Ahx-(Lys)4-[C3d]2 or N-acryloyl-Ahx-(Lys)4-[C3d]3 in the presence of 50 mole equivalents of acrylamide as a co-monomer to produce the peptide polymers; poly-PAS1K, poly-PAS1K+C3d, poly-PAS1K+[C3d]2 and poly-PAS1K+[C3d]3, respectively. Monomers (acryloyl-peptides and acrylamide) were dissolved in de-gassed polymerisation buffer (6 M guanidine-HCl containing 2 mM EDTA and 0.5 M Tris buffer, pH 8.) to yield a total monomer concentration of 2.5% w/v. Polymerization was initiated at room temperature and under nitrogen by the addition of 4% (w/w) ammonium persulfate of the molar concentration of monomers present and 5 μL of a 20% v/v TEMED solution in polymerization buffer.
After 18 hours the peptide polymers were dissolved in 50 mM ammonium bicarbonate and buffer exchanged using a Vivaspin 20 membrane column (GE Healthcare Life Sciences, NSW, Australia) at 8000 x g. The polymers were then purified via Gel Permeation Chromatography (GPC) using a Superdex 200 column (1.6 x 60 cm, GE Healthcare Life Sciences, NSW, Australia) installed in a 1100 HPLC system (Agilent Technologies Pty. Ltd., Victoria, Australia) with a flow rate of 0.5 ml/min, using an isocratic gradient of 50 mM ammonium bicarbonate as the running buffer. Detection was performed by UV absorbance at 214 nm. Isolated peptide polymers (>95% purity) were lyophilized using the Christ Freeze Dryer (Osterode am Harz, Germany) and stored at -20°C.

Immunisation Protocols
Animal experimentation was approved by the University of Melbourne animal ethics committee.  For the T-cell activation studies, BALB/c mice were immunised with 60μg of acryloyl-Ahx-(Lys)4-PAS1K peptide or 50μg of RgpA-Kgp complex (prepared as described by Pathirana et al.  ADDIN EN.CITE (Pathirana et al. 2006) in complete Freund’s adjuvant (CFA) in the hock of the hind legs. In further experiments BALB/c mice were immunised with 50μg of peptide or peptide polymer antigens: acryloyl-Ahx-(Lys)4-PAS1K peptide, poly-PAS1K, poly-PAS1K+C3d, poly-PAS1K+[C3d]2, poly-PAS1K+[C3d]3 in CFA.

T-cell Proliferation Assays
Seven days after immunisation lymphocytes were prepared from pooled inguinal and popliteal lymph nodes of BALB/c mice.  Lymph nodes and spleens were collected in enriched Dulbecco’s Modified Eagles Medium/Ham’s Nutrient Mixture F12 (DMEM) supplemented with 10% (v/v) heat inactivated (56ºC, 30 mins) foetal bovine serum (FBS), 2 mM glutamine, 2 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, 30 μg/mL gentamicin, 100 I.U./mL penicillin and 100 μg/mL streptomycin (JRH Biosciences, Parkville, Australia), L-arginine (116 mg/mL), L-asparagine (36 mg/mL), and folic acid (6 mg/mL, Sigma, Melbourne, Australia) and single cell suspensions made by passing the lymph nodes or spleens through a wire mesh (200 μm).
Red blood cells were removed from the spleen cell suspension by treatment with ammonium tris chloride buffer (17 mM Tris-HCl, 140 mM ammonium chloride in MilliQ water, pH 7.2) for five minutes at room temperature, and then washed three times in enriched DMEM (500 g, 5 mins at room temperature, IEC Centra GP8R refrigerated centrifuge, Thermo Electron Corporation, Melbourne, Victoria, Australia.).
	Monocytes and dead cells were removed from the lymph node cell suspension using Lympholyte®-M (Cedarlane® Laboratories Limited, Ontario, Canada) as per the manufacturers’ instructions.  Lymph node T-cells were separated using mouse CD 90 (Thy1.2) magnetic micro beads (catalogue number 130-049-101, Miltenyi Biotech, Germany) and the AutoMACs (Miltenyi Biotech, Germany) as per the manufacturers’ instructions.  T-cells were cultured in enriched DMEM at a concentration of 3 x 105 lymph node T-cells/well in a 96 well microtitre plate (Nunc, Denmark) in the presence of syngeneic γ-irradiated (2200 Rads) spleen cells (3 x 105cells/well) together with antigen: either acryloyl-Ahx-(Lys)4-PAS1K peptide or polymer antigens, poly-PAS1K, poly-PAS1K+C3d, poly-PAS1K+[C3d]2, poly-PAS1K+[C3d]3 (concentration 80 – 0.04 nmol/mL) or RgpA-Kgp complex (concentration 25 – 0.01 μg/well) in a total volume of 250 μL.  T-cells were incubated for four days at 37°C in an atmosphere of 5% CO2 in air.  One μCi 3H-thymidine (Amersham Pharmacia Biotech, UK) was added per well in the final 18 hours of incubation.  Cells were then lysed with cell lysis buffer (30 mM Tris-HCl, 100 mM EDTA, 1% N-Lauroylsarcosine, pH 8) and harvested onto glass fibre filter mats using a Tomtec Harvester96® MACH III cell harvester (Tomtec, Connecticut, USA).  The glass fibre filter mats were then air dried, and sealed in plastic bags containing 5 mL of Betaplate Scint (Perkin Elmer, N.S.W, Australia) and incorporation of 3H-thymidine was measured using a Wallac Microbeta Trilux Liquid Scintillation Counter (Perkin Elmer, N.S.W, Australia).  Data is expressed as stimulatory index (S.I.) ± SD where S.I. is calculated as the counts per minute (cpm) divided by the negative control cpm and statistically analysed using one-way ANOVA and Dunnett’s 3T test (SPSS for Windows, Release 6.0; SPSS)..

ELISPOT Assay
ELISPOT assay was performed using the Millipore Multiscreen 96-well filtration plates (MAHAS450, Millipore, N.S.W, Australia).  Plates were coated with anti-mouse cytokine capture antibodies (eBiosciences, San Diego, CA, USA), specific for IL-4 (catalogue number 14-7041, clone 11B11) and interferon-gamma (IFN-γ, catalogue number 14-7312, clone R4-6A2), at a concentration of 4 μg/mL in 0.1 M sodium bicarbonate buffer (pH 9.5) and incubated overnight at 4ºC.
	The ELISPOT plates were then washed with Dulbecco’s PBS and blocked with enriched DMEM for one hour at 37ºC.  Lymph node T-cells and spleens were prepared as above.  Antigen-primed lymph node cells (3 x 105/well) were incubated with γ-radiated (2200 Rads) syngeneic spleen cells as a source of APCs (3 x 105cells/well) and antigen: either RgpA-Kgp complex (5 μg/well) or acryloyl-Ahx-(Lys)4-PAS1K peptide or polymer antigens, poly-PAS1K, poly-PAS1K+C3d, poly-PAS1K+[C3d]2, poly-PAS1K+[C3d]3 (20 nmol/well).  Plates were incubated at 37ºC in an atmosphere of 5% CO2 in air for 48 hours in a humidified incubator.  The plates were then washed with phosphate buffered saline (PBS) containing 0.05% v/v Tween 20 (PBST) three times and once with MilliQ water.  Cytokine-specific biotinylated antibodies (eBiosciences, San Diego, CA, USA) specific for IL-4 (catalogue number 13-7042, clone BVD6-24G2) and IFN-γ (catalogue number 13-7311, clone XMG 1.2) were added at a concentration of 2 μg/mL in Dulbecco’s PBS/enriched DMEM (1:1, v/v) and incubated at room temperature for two hours.  Plates were washed six times with PBST and Streptavidin-Alkaline Phosphatase conjugate (Roche, Germany) was added to the plates at a 1:1000 dilution in Dulbecco’s PBS/enriched DMEM (1:1, v/v) and incubated for one hour at room temperature.  The plates were washed six times with PBST and three times with PBS, and 50 μL of substrate buffer (one tablet of 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium; BCIP/NBT, catalogue number B-565, Sigma-Aldrich, St Louis, MO, USA dissolved in 10 mL MilliQ water) was added per well.  Spots were allowed to develop for 20 – 30 minutes, before stopping the reaction by washing with water.  The spots were counted using EliSpot Reader Lite (version 2.9.  Autoimmun Diagnostika GmbH Ebinger Strasse 4, Strassberg, Germany).  Data is expressed as spot forming cells per million (SFC/million) and statistically analysed using one-way ANOVA and Dunnett’s 3T test (SPSS for Windows, Release 6.0; SPSS). 

Results and Discussion
Synthesis and polymerisation of peptide polymers
To investigate the ability of the C3d minimal binding epitope LYNVEA (C3d) to act as a molecular adjuvant we initially synthesised via solid phase peptide chemistry using standard FMOC chemistry protocols the C3d peptide monomers as acryloyl-Ahx- derivatives. Based on the reports that multi-sequential copies of C3d enhance immunity, mono- di and tri-sequential LYNVEA repeats were produced. These acryloyl-Ahx-[C3d]n peptides although successfully synthesised were difficult to solubilise and the yield of purified peptides was less than 1 mg from a 0.1 mmole scale synthesis. To address the solubility issue the peptides were synthesised with a four lysine spacer between the acryloyl-Ahx moiety and the N-terminus of the [C3d]n peptide.  The four lysine [(Lys)4)] spacer has been used in a number of studies to improve the solubility of peptides but also has an added benefit in that it functions as a cathepsin B cleavage site thus enhancing antigen processing at a site removed from the peptide epitope when it is incorporated into a macro-molecule  ADDIN EN.CITE (Rejmanova et al. 1983; Sarobe et al. 1993). With these features of the (Lys)4 motif in mind we synthesised the [C3d]n and PAS1K peptides as acryloyl-Ahx-(Lys)4 derivatives to enhance solubility and antigenicity, respectively. Furthermore, acryloyl-peptide monomers that are highly soluble in aqueous buffers were found to incorporate into polymers more readily  ADDIN EN.CITE (Jackson et al. 1997; O'Brien-Simpson et al. 1997). Figure 1A shows the HPLC chromatogram of the crude acryloyl-Ahx-(Lys)4-PAS1K (Ac-PAS1K) with the highlighted peak being the desired peptide and the inserted analytical HPLC chromatogram of the purified Ac-PAS1K (observed mass = 2312.7 Da, calculated mass = 2311.6 Da). The secondary product eluting earlier at 14.8 minutes was found to be a lysine deletion of Ac-PAS1K. The HPLC chromatogram of the crude acryloyl-Ahx-(Lys)4-[C3d]n (Ac-[C3d]n) peptide mixture for Ac-[C3d], Ac-[C3d]2 and Ac-[C3d]3 are shown in Figure 1B-D and clearly show one major synthetic product which corresponded to the desired peptide. For each sequential addition of C3d sequence (LYNVEA) there was an increase in the retention time of the peptide (Figure 1B-D) indicating an increasing hydrophobic nature of the minimal C3d binding sequence.
	The free radical polymerisation approach using ammonium persulphate and TEMED to initiate and activate co-polymerisation of the acryloyl-Ahx-(Lys)4-peptides and acrylamide was used and the reaction conditions were based on earlier reports  ADDIN EN.CITE (Jackson et al. 1997; O'Brien-Simpson et al. 1997). Similar to previous reports all of the peptide polymers eluted in the void volume of a size exclusion Superdex 200 column, which has an exclusion molecular weight of approximately 1.3 x 106 Da for globular structures (Figure 2A)  ADDIN EN.CITE (Jackson et al. 1997; O'Brien-Simpson et al. 1997). Amino acid analysis of the purified peptide polymers showed that the peptides contributed to 10-15% w/w of the polymers and the ratio of PAS1K to C3d peptide was similar to the peptide monomer ratio at the initiation of polymerisation (i.e 12.6% for Poly-PAS1K; 10.3% for Poly-PAS1K+[C3d] ratio 1:1.1; 14.7% for Poly-PAS1K+[C3d]2 ratio 1:0.9 and 12.8% for Poly-PAS1K+[C3d]3 ratio 1:0.9). These incorporation rates of peptides into acrylamide polymers are similar to those found by others {Jackson, 1997 #1231;O'Brien-Simpson, 1997 #1154}. Figure 2B shows a representative size exclusion profile of a PAS1K and [C3d]n co-polymer (Poly-PAS1K+[C3d]n) eluting in the void volume (14.8 mins) and the unreacted monomers eluting in the inclusion volume (38-46 mins). 
	Although all of the acryloyl-Ahx-(Lys)4-peptides could be polymerised with a small molecular weight co-monomer such as acrylamide none of the peptides formed polymers or oligomers in the abscence of a small molecular weight co-monomer as determined by size exclusion chromatography using Superdex 200 and Superdex-peptide columns to detect peptide polymers or oligomers, respectively (data not shown). Different acryloyl/vinyl monomers are known to preferentially form block co-polymers (Sandler and Karo 1992) and steric hindrance is considered to be a major factor for monomers not forming single monomer species polymers. Each of the acryloyl-Ahx-(Lys)4-peptides eluted at high acetonitrile (buffer B) concentrations, indicating significant hydrophobicity (Figure 1). In the aqueous polymerisation buffer, this high level of hydrophobicity may result in increased steric hindrance about the acryloyl moiety, effectively suppressing free radical transfer in the polymerization reaction (Zou et al. 1993).  As a consequence, each of the peptide polymers - either containing a single peptide (PAS1K) or the heteropolymeric (PAS1K+[C3d]n) - are likely to be block co-polymers.

T cell proliferative and cytokine responses induced by the peptide polymers
A number of studies have shown that incorporation of C3d tandem repeats of either the whole protein sequence or peptides incorporating the CD21 binding site sequence into DNA-, recombinant protein-, or peptide- based immunogens enhances immunity to the co-immunised antigen  ADDIN EN.CITE (Bergmann-Leitner et al. 2007; Bower and Ross 2006; Lou and Kohler 1998; Servis and Lambris 1989; Tsokos et al. 1990; Zhang et al. 2011). Furthermore, Servis and Lambris (1989) have shown that four copies of a 13 residue C3d peptide pendent from ε-amino groups of lysine residues in a linear peptide template was sufficient to enhance T cell proliferation by cross-linking the CD21 receptor on the T cell and the antigen presenting cell. Free radical polymerisation of the minimal CD21 binding sequence LYNVEA from C3d and tandem repeats of it would incorporate into one immunogen both valency features known to enhance immunity. Using the PAS1K+[C3d]n polymers we were able to investigate whether; the minimal CD21 binding sequence is sufficient to enhance immunity and if copy number or tandem repeats of LYNVEA induce a larger effect. 
	To investigate whether the peptide polymers would enhance antigen specific T cell responses, mice were immunised with either the PAS1K peptide or the native antigen the RgpA-Kgp complex and after 7 days the isolated lymph node T cells were stimulated in-vitro with peptide and peptide polymers. Figure 3 shows the T cell proliferative responses of antigen primed and antigen stimulated T cells with the typical proliferative profiles of a maximal stimulation at a certain antigen concentration followed by inhibition of T cell stimulation at higher antigen doses via anergy and/or apoptosis {Falk, 2000 #8519;LaSalle, 1994 #8520}. Figure 3A shows that PAS1K peptide primed T cells when incubated with PAS1K peptide had a maximal proliferative response at an antigen concentration of 40 nmol. Similarly, Poly-PAS1K+[C3d]2 and Poly-PAS1K+[C3d]3 both induced a maximal T cell response at an antigen concentration of 40 nmol, with Poly-PAS1K+[C3d]2 inducing a significantly (p<0.05) stronger T cell response compared to PAS1K peptide and Poly-PAS1K+[C3d]3 stimulated T cells. Interestingly, Poly-PAS1K and Poly-PAS1K+[C3d] did not induce a T cell response in the PAS1K primed T cells. For RgpA-Kgp complex primed T cells Poly-PAS1K+[C3d]2 and Poly-PAS1K+[C3d]3 both induced a significantly (p<0.05) stronger T cell response compared to that induced by the PAS1K peptide (Figure 3B). Although Poly-PAS1K did not induce a T cell response in the RgpA-Kgp complex primed T cells, Poly-PAS1K+[C3d] induce a T cell response at an antigen concentration of 20 nmol, albeit, significantly (p<0.05) weaker than that induced by the other stimulating antigens.
	The lack of stimulation of T cells with Poly-PAS1K and Poly-PAS1K+[C3d] may be due to antigen processing of the PAS1K peptide from the polymer back bone, resulting in the cleavage of the PAS1K peptide within the T cell epitope, thus reducing the amount of antigen available. Several studies have shown that conjugation of a T cell epitope into a construct reduces T cell stimulation as the epitope in the peptide construct is enzymatically hydroysed during antigen processing, not necessary for free peptide, which reduces the amount of stimulatory peptide presented via MHC class II to T cells {Dyrberg, 1986 #8515;Fitzmaurice, 2000 #8518;Lu, 1991 #8516;Partidos, 1992 #8517}. The C3d tandem repeat peptide polymers Poly-PAS1K+[C3d]2 and Poly-PAS1K+[C3d]3 both induced a strong proliferative response. Several studies have shown that tandem repeats of C3d peptides enhances immunity to the co-immunised antigen by lowering the antigenic stimulation threshold  ADDIN EN.CITE (Bower and Ross 2006; Haas et al. 2004; Servis and Lambris 1989; Zhang et al. 2011). Assuming that PAS1K is processed in a similar way for all of the peptide polymers, the inclusion of at least two tandem repeats of the minimal C3d sequence LYNVEA into the peptide polymers rather than a single copy were sufficient to reduce the antigenic threshold so that the available peptide (PAS1K) was more efficient at stimulating a T cell proliferative response.
	To investigate whether the C3d peptide polymers could enhance immunity in-vivo, mice were immunised with each peptide polymer and the PAS1K peptide and the ability of the antigen primed T cells to proliferate was evaluated using the native antigen the RgpA-Kgp complex in-vitro. Figure 3C shows that the PAS1K peptide and Poly-PAS1K primed T cells had maximal proliferative responses at 3.13 and 1.56 μg/well of RgpA-Kgp complex, respectively and that the PAS1K peptide primed T cells had a significantly (p<0.01) stronger response compared to Poly-PAS1K primed T cells. All of the PAS1K+C3d peptide polymer primed T cells had maximal proliferative responses at a stimulating antigen concentration of 0.02 μg/well which was significantly (p<0.05) lower concentration than that of the maximal proliferative response by the PAS1K peptide or Poly-PAS1K-primed T cells. Furthermore, the total T cell numbers isolated from the PAS1K+C3d peptide polymer immunised mice was consistently 10% higher in each experiment compared to T cell numbers isolated from PAS1K peptide and Poly-PAS1K immunised mice.
	The ability of C3d containing peptide polymers to enhance immunity to a far greater extent in-vivo than in-vitro may be due to the immunostimulatory effects of C3d on the antigen presenting cells. CD21 the receptor for C3d is known to be up regulated on APCs upon activation, thus enhancing cross-linking of APC’s and T cells via CD21/C3d ligation and reducing the T cell activation threshold (Allison 1998). This would result in an increase of the polydiversity of the antigen specific T cell repertoire and their proportion within the whole T cell population. APC’s in in-vitro assays are treated chemically or with radiation to prevent them from proliferating and generating proteins. Thus, unlike in-vivo-APC’s, in-vitro-APC’s would not be able to up regulate CD21 on their surface, which may account for why the C3d containing peptide polymers were able to enhance a stronger immune response when used to immunise rather than stimulate.
	To further investigate the effects of the C3d containing peptide polymers, T cells isolated from antigen primed mice were stimulated with antigen in-vitro and the IFNγ and IL-4 cytokines secreted were analysed by ELISPOT (Figure 4). PAS1K peptide and Poly-PAS1K+[C3d]3 induced a mixed IL-4 and IFNγ response in PAS1K-primed T cells, whereas Poly-PAS1K+[C3d] and Poly-PAS1K+[C3d]2 induced a significantly (p<0.05) stronger IL-4 response (Figure 4A). In RgpA-Kgp complex primed T cells the PAS1K peptide stimulated a mixed IL-4 and IFNγ response (Figure 4B). Poly-PAS1K induced a significantly (p<0.05) weaker IL-4 and IFNγ response compared to that induced by the other peptide polymers or PAS1K peptide. All of the PAS1K+C3d containing polymers induced a mixed IL-4 and IFNγ response which was significantly (p<0.05) stronger than the response induced by the PAS1K peptide with the RgpA-Kgp complex-primed T cells (Figure 4B). Figure 4C shows the IL-4 and IFNγ response induced by the RgpA-Kgp complex on PAS1K peptide and peptide polymer primed T cells. The RgpA-Kgp complex induced a mixed IL-4 and IFNγ response in PAS1K primed T cells, whereas Poly-PAS1K primed T cells had a predominant IL-4 cytokine response. In contrast, all of the Poly-PAS1K+[C3d]n primed T cells had a predominantly and significantly (p<0.05) higher IFNγ response compared to the response of PAS1K peptide or Poly-PAS1K primed T cells, indicating that C3d may promote a Th1 cell phenotype.
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Figure 1:  
Analytical Reverse phase-HPLC profiles of synthetic acryloyl-peptides. Reversed phase HPLC (RP-HPLC) profile of crude acryloyl-peptides with the corresponding analytical RP-HPLC of the purified acryloyl-peptide and ES-MS observed mass (insert) of; (A) acryloyl-PAS1K, expected molecular weight [m/z 2312.6 (M+H)+], (B) acryloyl-C3d, expected molecular weight [m/z 1388.7 (M+H)+], (C) acryloyl-[C3d]2, expected molecular weight [m/z 2078.5 (M+H)+], and (D) acryloyl-[C3d]3, expected molecular weight m/z 2768.2 (M+H)+]. RP-HPLC was performed using a semi-preparative Zorbax 300 SB-C18 column installed in a HPLC system. Peptide separation was achieved using 0-100% buffer B (0.1% TFA in 90% acetonitrile, 10% milliQ water, v/v) gradient over a period of 30 min at a flow rate of 4.0 ml/min.

Figure 2:  Size exclusion chromatography profiles of crude synthetic polymers. (A) Size exclusion chromatography profile of Poly-PAS1K. Elution times of the standards, Thyroglobulin (A, MW: 669kDa), Ferritin (B, MW: 440kDa) and Catalase (C, MW: 232kDa) are indicated by vertical arrows. (B) Size exclusion chromatography profile of Poly-PAS1K+[C3d]3, collected from time 15.0-17.0 min as indicated by the vertical lines. Size exclusion chromatography was performed using a Superdex 200 column installed in a HPLC system. Separation was based on molecular size using an isocratic gradient of 50 mM ammonium bicarbonate as the running buffer at a flow rate of 0.5 ml/min. Detection was performed by absorbance at 214 nm.

Figure 3:  T-cell proliferative responses induced by peptide polymers.  T-cells were isolated from the popilteal and inguinal lymph nodes of BALB/c seven days after immunisation with antigen (peptide, peptide-polymer or the RgpA-Kgp complex) and then re-stimulated in-vitro to determine T cell proliferative response. T-cells were isolated from PAS1K peptide (A) and RgpA-Kgp complex (B) immunised mice and were incubated with γ-irradiated syngeneic spleen cells and either PAS1K peptide () or peptide polymer; Poly-PAS1K (), Poly-PAS1K+C3d (), Poly-PAS1K+[C3d]2 () or Poly-PAS1K+[C3d]3 (), concentration of the stimulating antigen was based on PAS1K. (C), T-cells isolated from antigen (PAS1K peptide () or peptide polymer; Poly-PAS1K (), Poly-PAS1K+C3d (), Poly-PAS1K+[C3d]2 () or Poly-PAS1K+[C3d]3 ()) immunised mice and were incubated with γ-irradiated syngeneic spleen cells and the native antigen the RgpA-Kgp complex. T-cell proliferation was measured using 3H-thymidine incorporation for the last 18 hours of the assay and is expressed as the stimulatory index (S.I.).  Data is representative of duplicate assays ± SD.

Figure 4:  T-cell cytokine responses induced by peptide polymers.  T-cells were isolated from the popilteal and inguinal lymph nodes of BALB/c seven days after immunisation with antigen (peptide, peptide-polymer or the RgpA-Kgp complex) and then re-stimulated in-vitro to determine the antigen-specific IL-4 and IFNγ secretion response. T-cells were isolated from the PAS1K peptide (A) and RgpA-Kgp complex (B) immunised mice and were incubated with γ-irradiated syngeneic spleen cells and either PAS1K peptide or peptide polymer (Poly-PAS1K, Poly-PAS1K+C3d, Poly-PAS1K+[C3d]2 or Poly-PAS1K+[C3d]3), concentration of the stimulating antigen was based on PAS1K. (C), T-cells isolated from antigen (PAS1K peptide or peptide polymer; Poly-PAS1K, Poly-PAS1K+C3d, Poly-PAS1K+[C3d]2 or Poly-PAS1K+[C3d]3 immunised mice and were incubated with γ-irradiated syngeneic spleen cells and the native antigen the RgpA-Kgp complex. IL-4 and IFNγ T-cell cytokine responses were determined after 2 days of incubation. Data is expressed as spot forming cells per million (SFC) ± SD minus the background, and is representative of triplicate or duplicate assays. 
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